» Articles » PMID: 35123548

Altered Central and Blood Glutathione in Alzheimer's Disease and Mild Cognitive Impairment: a Meta-analysis

Abstract

Background: Increasing evidence implicates oxidative stress (OS) in Alzheimer disease (AD) and mild cognitive impairment (MCI). Depletion of the brain antioxidant glutathione (GSH) may be important in OS-mediated neurodegeneration, though studies of post-mortem brain GSH changes in AD have been inconclusive. Recent in vivo measurements of the brain and blood GSH may shed light on GSH changes earlier in the disease.

Aim: To quantitatively review in vivo GSH in AD and MCI compared to healthy controls (HC) using meta-analyses.

Method: Studies with in vivo brain or blood GSH levels in MCI or AD with a HC group were identified using MEDLINE, PsychInfo, and Embase (1947-June 2020). Standardized mean differences (SMD) and 95% confidence intervals (CI) were calculated for outcomes using random effects models. Outcome measures included brain GSH (Meshcher-Garwood Point Resolved Spectroscopy (MEGA-PRESS) versus non-MEGA-PRESS) and blood GSH (intracellular versus extracellular) in AD and MCI. The Q statistic and Egger's test were used to assess heterogeneity and risk of publication bias, respectively.

Results: For brain GSH, 4 AD (AD=135, HC=223) and 4 MCI (MCI=213, HC=211) studies were included. For blood GSH, 26 AD (AD=1203, HC=1135) and 7 MCI (MCI=434, HC=408) studies were included. Brain GSH overall did not differ in AD or MCI compared to HC; however, the subgroup of studies using MEGA-PRESS reported lower brain GSH in AD (SMD [95%CI] -1.45 [-1.83, -1.06], p<0.001) and MCI (-1.15 [-1.71, -0.59], z=4.0, p<0.001). AD had lower intracellular and extracellular blood GSH overall (-0.87 [-1. 30, -0.44], z=3.96, p<0.001). In a subgroup analysis, intracellular GSH was lower in MCI (-0.66 [-1.11, -0.21], p=0.025). Heterogeneity was observed throughout (I >85%) and not fully accounted by subgroup analysis. Egger's test indicated risk of publication bias.

Conclusion: Blood intracellular GSH decrease is seen in MCI, while both intra- and extracellular decreases were seen in AD. Brain GSH is decreased in AD and MCI in subgroup analysis. Potential bias and heterogeneity suggest the need for measurement standardization and additional studies to explore sources of heterogeneity.

Citing Articles

UHPLC-Q Exactive-Orbitrap-MS and network pharmacology analyses to investigate the mechanism by which Danggui-Shaoyao-San affects 27-OHC-induced cell damage in SH-SY5Y/C6 coculture.

Huang Y, Zhai Y, Zhao D, Wu M, Shen Q, Zhao W BMC Complement Med Ther. 2025; 25(1):75.

PMID: 39994624 PMC: 11849221. DOI: 10.1186/s12906-025-04751-y.


Iron-associated lipid peroxidation in Alzheimer's disease is increased in lipid rafts with decreased ferroptosis suppressors, tested by chelation in mice.

Thorwald M, Godoy-Lugo J, Garcia G, Silva J, Kim M, Christensen A Alzheimers Dement. 2025; 21(1):e14541.

PMID: 39876821 PMC: 11775463. DOI: 10.1002/alz.14541.


Oral prodrug of a novel glutathione surrogate reverses metabolic dysregulation and attenuates neurodegenerative process in APP/PS1 mice.

Rao S, Imam-Fulani A, Xie W, Phillip S, Chennavajula K, Lind E bioRxiv. 2025; .

PMID: 39868172 PMC: 11761491. DOI: 10.1101/2025.01.15.633247.


Neuroprotective Potential of L. Essential Oil Against Scopolamine-Induced Memory Deficits and Oxidative Stress in a Zebrafish Model.

Brinza I, Boiangiu R, Honceriu I, Abd-Alkhalek A, Osman S, Eldahshan O Biomolecules. 2025; 15(1).

PMID: 39858532 PMC: 11762835. DOI: 10.3390/biom15010138.


Glutamine metabolism is systemically different between primary and induced pluripotent stem cell-derived brain microvascular endothelial cells.

Weber C, Moiz B, Kheradmand M, Scott A, Kettula C, Wunderler B J Cereb Blood Flow Metab. 2025; 271678X241310729.

PMID: 39763385 PMC: 11705297. DOI: 10.1177/0271678X241310729.


References
1.
Oeltzschner G, Wijtenburg S, Mikkelsen M, Edden R, Barker P, Joo J . Neurometabolites and associations with cognitive deficits in mild cognitive impairment: a magnetic resonance spectroscopy study at 7 Tesla. Neurobiol Aging. 2018; 73:211-218. PMC: 6294473. DOI: 10.1016/j.neurobiolaging.2018.09.027. View

2.
Kurup R, Kurup P . Hypothalamic digoxin, hemispheric chemical dominance, and Alzheimer's disease. Int J Neurosci. 2003; 113(3):361-81. DOI: 10.1080/00207450390162146. View

3.
Kosenko E, Aliev G, Kaminsky Y . Relationship between chronic disturbance of 2,3-diphosphoglycerate metabolism in erythrocytes and Alzheimer disease. CNS Neurol Disord Drug Targets. 2015; 15(1):113-23. DOI: 10.2174/1871527314666150821103444. View

4.
Gonzalez-Riano C, Tapia-Gonzalez S, Garcia A, Munoz A, DeFelipe J, Barbas C . Metabolomics and neuroanatomical evaluation of post-mortem changes in the hippocampus. Brain Struct Funct. 2017; 222(6):2831-2853. PMC: 5541081. DOI: 10.1007/s00429-017-1375-5. View

5.
Sadhu A, Upadhyay P, Agrawal A, Ilango K, Karmakar D, Singh G . Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product. Clin Drug Investig. 2014; 34(12):857-69. DOI: 10.1007/s40261-014-0235-9. View